This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Arzneimittelkommission der deutschen Ärzteschaft (2009): Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie. 22. Auflage, Medizinische Medien Informations GmbH (MMI) Neu-Isenburg, S. 823–835
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K,
Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010): Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071–1081
Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. (2008):
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet; 371: 651–659
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528
Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J,
Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR, Dunitz J, Murray FT (2006): Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 32: 25826–3
Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bon- not-Marlier S (2005): Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21: 805–812
Bouras EP, Scolapio JS (2004): Gastric motility disorders: management that optimizes nutrition- al status. J Clin Gastroenterol 38: 549-557.Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008): A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344–2354
Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008): A placebo-controlled trial of prucalo- pride for severe chronic constipation. N Engl J Med 358: 2344–2354
Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW,
Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110
Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244
Corley DA, Kubo A, Zhao W, Quesenberry C (2010): Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastro- enterology 139: 93–101
Cornberg M, Höner zu Siederdissen C, Maasoumy B, Manns MP (2014): Neue direkt antivirale Medikamente zur Behandlung der chronischen Hepatitis C 2014. Internist 55: 390–400
Depta JP, Bhatt DL (2012): Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 27: 642–650
De Vrese M, Marteau PR (2007): Probiotics and prebiotics: effects on diarrhea. J Nutr 137(3 Suppl 2): 803S–811S
Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L (2012): Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 35: 48–55
Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J (2014): Adalimumab therapy is associated with reduced risk of hospitali- zation in patients with ulcerative colitis. Gastroenterology 146: 110–118
Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM; ask Force on the Management of Functional Bowel Disorders (2014): American Col- 796
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mössner, J. (2015). Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_30
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)